The Challenge Of Tuberculosis To The Global Public Health Care: A Clinical Pharmacist Perspective | 22479
Journal of Bioanalysis & Biomedicine
Like us on:
Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.
Tuberculosis (TB) is an infectious disease caused by bacillus Mycobacterium tuberculosis. TB remains a major cause of
morbidity and mortality with an estimated 8.6 million new TB cases and 1.3 million TB deaths in 2012. The emergence
of Multi drug resistant TB (MDR-TB) especially in developing countries like India where there is a high burden of TB cases
has added to further vows against fight towards TB. Drug resistant forms are hard to treat and are resistant to first line anti
TB drugs and requires a therapy of 20 months with low success rates, leading to non compliance to the therapy in many cases.
Government of India has amended Drug and Cosmetic act 1947, incorporating anti TB drugs in Schedule-H1 banning it
OTC aiming to prevent misuse of drugs to stop drug resistance which needs to be applauded, but a Clinical pharmacist with
his broad spectrum of knowledge is the person who can work on the ground and can change the attitude of a patient towards
this infectious disease by motivating and counseling the patient for proper utilization of the drugs and can play a vital role in
reducing the TB burden. It is the need of the hour that the duties of clinical pharmacist should be exploited in India which can
be beneficial to both the patients and country to attain an atmosphere of wellbeing and a healthy society.
Khadeer Ahmed Ghori is a PharmD 5th year student of MESCO College of Pharmacy, Hyderabad, India which is affiliated to Osmania University.
Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals